Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-6473|22|9|1295-1300

ISSN： 1527-6465

Source： LIVER TRANSPLANTATION, Vol.22, Iss.9, 2016-09, pp. : 1295-1300

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

PNPLA3 as a liver steatosis risk factor following living‐donor liver transplantation for hepatitis C

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E335-E339

John Wiley & Sons Inc

Access to resources Recommend Favorite

Better innovate than compromise: A novel hepatic outflow reconstruction technique in pediatric living donor liver transplantation

By  

PEDIATRIC TRANSPLANTATION, Vol. 19, Iss. 3, 2015-05 ,pp. : E56-E61

John Wiley & Sons Inc

Access to resources Recommend Favorite

Technique advance to avoid hepatic venous outflow obstruction in pediatric living‐donor liver transplantation

By  

PEDIATRIC TRANSPLANTATION, Vol. 19, Iss. 3, 2015-05 ,pp. : 261-266

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal line of hepatotomy for left lateral living donor liver transplantation according to the anatomical variations of left hepatic duct system

By  

PEDIATRIC TRANSPLANTATION, Vol. 19, Iss. 5, 2015-08 ,pp. : 510-516

John Wiley & Sons Inc

Access to resources Recommend Favorite

De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 11, 2015-11 ,pp. : 1395-1402

John Wiley & Sons Inc

Access to resources Recommend Favorite